Navigating Phase II and Phase III Clinical Trials in the US and EU: Trends, Challenges, and Best Practices

Phase II and Phase III clinical trials are critical to regulatory approval—but navigating them across the U.S. and EU introduces added complexity. This white paper explores the evolving regulatory landscapes, operational challenges, and methodological innovations shaping late-stage clinical development in both regions. It provides practical guidance on trial design, regulatory strategy, patient recruitment, data quality, and best practices to help you execute global Phase II/III programs efficiently, compliantly, and with confidence.